Blair William & Co. IL Purchases 35,757 Shares of PDS Biotechnology Co. (NASDAQ:PDSB)

Blair William & Co. IL raised its position in PDS Biotechnology Co. (NASDAQ:PDSB) by 29.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 157,500 shares of the company’s stock after buying an additional 35,757 shares during the period. Blair William & Co. IL owned 0.42% of PDS Biotechnology worth $257,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Geode Capital Management LLC grew its position in PDS Biotechnology by 9.8% during the 3rd quarter. Geode Capital Management LLC now owns 415,113 shares of the company’s stock worth $1,586,000 after acquiring an additional 37,142 shares during the last quarter. Virtu Financial LLC bought a new stake in shares of PDS Biotechnology during the fourth quarter worth $89,000. XTX Topco Ltd increased its stake in shares of PDS Biotechnology by 241.8% in the third quarter. XTX Topco Ltd now owns 67,182 shares of the company’s stock valued at $257,000 after buying an additional 47,528 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new position in shares of PDS Biotechnology in the fourth quarter valued at about $26,000. 26.84% of the stock is owned by institutional investors.

Analyst Ratings Changes

Separately, HC Wainwright lowered their price objective on shares of PDS Biotechnology from $21.00 to $13.00 and set a “buy” rating for the company in a research report on Thursday, March 27th. One equities research analyst has rated the stock with a sell rating, three have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $9.00.

PDS Biotechnology Stock Performance

Shares of PDS Biotechnology stock opened at $0.95 on Friday. The firm has a fifty day moving average of $1.36 and a two-hundred day moving average of $2.08. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.84 and a current ratio of 2.84. The stock has a market capitalization of $43.13 million, a price-to-earnings ratio of -0.82 and a beta of 1.50. PDS Biotechnology Co. has a 52 week low of $0.91 and a 52 week high of $4.42.

PDS Biotechnology (NASDAQ:PDSB) last released its quarterly earnings data on Thursday, March 27th. The company reported ($0.21) EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.08. As a group, equities research analysts predict that PDS Biotechnology Co. will post -1.2 EPS for the current year.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.